Anebulo Pharmaceuticals (ANEB) Expected to Announce Earnings on Thursday

Anebulo Pharmaceuticals (NASDAQ:ANEB) is expected to announce its Q3 2026 resultson Thursday, May 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings data on Friday, February 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.08.

Anebulo Pharmaceuticals Stock Up 5.3%

Shares of NASDAQ:ANEB opened at $0.48 on Tuesday. The firm’s 50 day moving average price is $0.61 and its 200-day moving average price is $1.33. Anebulo Pharmaceuticals has a twelve month low of $0.30 and a twelve month high of $3.42. The stock has a market capitalization of $19.75 million, a PE ratio of -2.55 and a beta of -1.93.

Hedge Funds Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned 0.12% of Anebulo Pharmaceuticals as of its most recent SEC filing. Institutional investors own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical?stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.